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Background: Pleural invasion status is known to be a predictor of survival after pulmonary resection for non-small
cell lung cancer. Our goal was to determine whether the length of tumor attachment to the pleura on a pretreatment
CT image has prognostic value as an alternative to pleural invasion status for stage I non-small cell lung cancer treated
with stereotactic body radiotherapy (SBRT).
Methods: A total of 90 tumors in 87 patients (males: 68, females: 19) who received SBRT between March 2005 and
September 2011 in our institution were reviewed. The median age of the patients was 78 years (range, 48-90 years).
The median tumor diameter was 2.2 cm (range, 0.9-4.2 cm). The prescribed dose was typically 48 Gy in 4 fractions,
60 Gy in 8 fractions or 60 Gy in 15 fractions to the isocenter with 6 MV X-ray using 4 non-coplanar and 3 coplanar static
beams. The lengths of attachment were measured using pretreatment CT images at the lung window. Cumulative
incidence rates were calculated using Kaplan-Meier curves, and univariate and multivariate analyses for in-field
tumor control, locoregional control (LRC), freedom from distant metastasis and freedom from progression (FFP)
were performed using a Cox proportional hazards model.
Results: Of the 90 tumors, 42 tumors were attached to the pleura (median, 14.7 mm; range, 4.3-36.0 mm), 21
tumors had pleural indentation and 27 tumors had no attachment. The median follow-up period for survivors
was 46.1 months. The 3-year in-field control, LRC, FFP and overall survival rates were 91.2%, 75.3%, 63.8% and
68.6%, respectively. SBRT dose and tumor diameter were independently significant predictors of in-field control
(p = 0.02 and p = 0.04, respectively). Broad attachment to the pleura, the length being more than 14.7 mm, was a
negative independent predictor of LRC and FFP (p = 0.02 and p = 0.01, respectively).
Conclusions: Pleural attachment status on a pretreatment CT image might be an important predictor of LRC and FFP.
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Among the various lung cancer treatment options, surgical
resection has been the standard treatment for early-stage
non-small cell lung cancer (NSCLC), and relationships
between treatment outcomes and clinical, operative or
pathological findings have been reported. Based on these
findings, the staging system has been revised and the
Union Internationale Contre le Cancer (UICC) TNM
classification of malignant tumors 7th edition is now in
worldwide use [1,2]. According to the TNM classification
for lung cancer, pathological findings of visceral pleural in-
vasion beyond the elastic layer (pl1), invasion to the
pleural surface (pl2) or invasion to the interlobar pleura
(pl3) is upgraded to T2a and therefore upstaged to stage
IB even if the tumor diameter is 3 cm or less. In contrast,
a tumor of 3 cm or less in diameter with superficial pleural
invasion beneath the elastic layer (pl0) remains T1 and
therefore remains stage IA. This precise definition of
visceral pleural invasion referring to the status of the
elastic layer is one of the changes from the TNM 6th
edition to the TNM 7th edition [3]. Reports about the
prognostic value of visceral pleural invasion after a lung
operation have been published since the revision, and
there has been a report about the relationship between
presurgical computed tomography (CT) images and
pathological difference: pl1, pl2 and pl3 [4-6].
On the other hand, stereotactic body radiotherapy (SBRT)
is a relatively new treatment. However, with progress in
the SBRT technique, better treatment outcomes and
higher local control rate for stage I NSCLC have been
reported [7-11]. Although a lung operation is a standard
treatment for early-stage NSCLC, SBRT is often chosen al-
ternatively as a curative treatment if operative risks are ex-
pected to overcome the benefit [12]. SBRT is an important
treatment option for medically inoperable patients and for
patients who have refused surgery [13]. For further pro-
gress in the technique, many prognostic factors from clin-
ical and technological points of view have been reported.
For instance, T stage, standardized uptake value (SUVmax)
on 18 F-fluorodeoxyglucose positron emission tomog-
raphy and biological effective dose (BED) have been re-
ported as predictors of outcomes [9-11,14-16].
The prognostic significance of pleural invasion status
after treatment of stage I NSCLC with SBRT has rarely
been discussed because gross pathology or microscopic
pathology cannot be clarified as in an operation. By tak-
ing surgical outcomes into consideration, tumor invasion
to the pleura beyond the elastic layer probably affects the
treatment outcome and might be a predictor of outcome
after SBRT, although there has been only one report about
pleural contact to the pleura on a CT image [17]. Al-
though the pathological pleural invasion status cannot
be determined in SBRT, we hypothesized that the length
of tumor attachment to the pleura on a pretreatment CTimage may be an alternative to pathological findings, with
broad attachment to the pleura representing tumor inva-
sion beyond the elastic layer, and may have prognostic
value. The purpose of this study was to investigate the
impact of tumor attachment to the pleura on outcome
of stage I NSCLC treated with SBRT by measuring the
attachment length with a pretreatment CT image.
Methods
Patients
We reviewed our clinical retrospective database, and 110
patients (114 lesions) with stage I NSCLC were treated
with SBRT form March 2005 through November 2011.
Patients with follow-up of less than 3 months, patients
with tumors having mainly a ground glass opacity com-
ponent and patients with tumors that could not be mea-
sured on axial and coronal sections of pretreatment CT
images were excluded. Ninety tumors in 87 consecutive
patients were used for analysis in this study. The main
clinical and pathological characteristics are summarized
in Table 1. This retrospective study was approved by the
Ethical Committee of Tohoku University Hospital (No.
2011-228) and informed consent was obtained from all
patients.
Pretreatment CT images and measurements
Chest imaging for all tumors was performed with a mul-
tidetector CT scanner. In our institute, thoracic CT
scanning has usually been performed using SOMATOM
Definition (Siemens, Forchheim, Germany), Aquilion
64 (Toshiba Medical Systems, Nasushiobara, Japan) or
Robusto (Hitachi Medico, Tokyo, Japan) with breath
hold and with or without injection of an intravenous
contrast material because the attachment lengths of all
tumors were measured at window settings for the lung
(center, -700 HU; width, 1500 HU). The scanning pa-
rameters were 120 kVp and an auto milliampere setting
(100-220 milliamperes). Slice thickness ranged from
1.0 mm to 10 mm, and the median and mean slice thick-
nesses were 2.0 mm and 2.5 mm, respectively.
Positive pleural attachment was defined as tumor at-
tachment to the visceral pleura on CT images at both the
lung window and mediastinal window (center, 45 HU;
width, 320 HU) or tumor attachment to the interlobar
pleura at the lung window. Positive pleural indentation
was defined as tumor indentation to the visceral pleura on
CT images at the lung window. Maximum tumor diam-
eter, tumor attachment and indentation to the pleura, and
length of tumor attachment to the pleura were measured
using AquariusNET Viewer (TeraRecon, Foster City, CA)
at the lung window with axial and coronal sections.
The length of tumor attachment was the sum of mea-
surements of short lines along the pleural attachment
surface (Figure 1).
Table 1 Patients and tumor characteristics
Characteristic No. (%)








Tumor diameter, median, cm 2.2 (range: 0.9-4.2)





Squamous cell carcinoma 20 (22)
Others 8 (8)
Clinically diagnosed 30 (33)
SBRT dose, BED10
≤ 102 Gy10 44 (48)




Data are shown as number (percentage) of patients for parameters from age to
performance status and as number (percentage) of tumors for other parameters.
Abbreviations: ECOG, Eastern cooperative oncology group; BED10, biological
effective dose, calculated by the formula BED = nd [1 + d/(α/β)], where n is the
number of fractions, d is the dose/fraction, and α/β ratio is 10 Gy for tumors;
D95, doses covering 95% of the planning target volume.
Figure 1 Length of tumor attachment to the pleura were measured at t
pleura (a), tumor attachment to the interlobar pleura (b), tumor attachment t
pleura at a coronal section (d).
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We previously reported details of the SBRT technique
[18]. The patient was immobilized in the supine position
in a body frame (Vac-loc, Med-tek, Orange City, IA)
with or without an abdominal pressure belt based on
tumor location and tumor (or implanted gold marker)
breathing motion on fluoroscopic movies by a simulator
(Ximatron, Varian Medical Systems, Palo Alto, CA), and
tumor (or implanted gold marker) breathing motion was
subsequently measured. Then a slow-rotation serial CT
scan in the same position was performed at intervals of
2.5 mm and acquisition time of 4 seconds. Internal mar-
gins were formed by both the motion measurement on
fluoroscopy and tumor blurring on a slow-rotation CT.
Gross tumor volume (GTV) was defined as the visible
extent of the tumor on a slow-rotation scanning CT image
at the lung window, and clinical target volume was defined
as GTV plus a 0-5 mm margin for microscopic invasion.
For set-up uncertainty, set-up margins of 5 mm and daily
on-board imager (Varian Medical Systems, Palo Alto, CA)
were required. Treatment was performed using 6 MV
photons with 5 to 7 coplanar or non-coplanar multi-static
beams. The SBRT plan was created with the Eclipse plan-
ning system (Varian Medical Systems, Palo Alto, CA).
Before June 2009, the pencil beam method with hetero-
geneity correction (modified Batho power law) was utilized
for planning, and 48 Gy in 4 fractions, 60 Gy in 8 fractions
or 60 Gy in 15 fractions was delivered to the isocenter.
After June 2009, an analytical anisotropic algorithm (AAA)
was utilized for planning, and 40 Gy in 4 fractions or
50 Gy in 8 fractions covering 95% of the PTV (D95) was
delivered. The prescription dose of 40 Gy in 4 fractions or
50 Gy in 8 fractions is similar to 48 Gy in 4 fractions or
60 Gy in 8 fractions to the isocenter, respectively. Thehe lung window. Measurements of tumor attachment to the visceral
o the pleura in non-high-resolution CT (c), tumor attachment to the
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ance status. Eight or 15 fractions were selected if the lung
tumor was adjacent to critical organs such as the main
bronchus, heart and esophagus but not the chest wall.
SBRT was performed on consecutive treatment days. The
isocenter doses were recalculated with AAA (version
11031), and then BED10 was calculated using the following
formula: BED10 = nd [1 + d/(α/β)], where n is the number
of fractions, d is the isocenter dose per fraction, and
α/β ratio is 10 Gy for the tumor. Median BED10 was
102.1 Gy10 (range: 74.2-121.0 Gy10).
Follow-up and evaluation
Follow-up procedures have been reported elsewhere [18].
Follow-up examinations by a radiation oncologist were
performed every 3-6 months for 2 years after SBRT and
then every 6 months. Patients also underwent examina-
tions by physicians. In-field control was defined as tumor
control within the 95% isodose line, and locoregional
control (LRC) was defined as disease control within the
treated lobe and hilar or mediastinal lymph node. The
final diagnosis of any control failure was made by phy-
sicians and radiation oncologists. Toxicity was graded
using the National Cancer Institute Common Termin-
ology Criteria for Adverse Events ver. 4.0.
Statistical analysis
Time to an event was calculated from the first day of
SBRT to the day an event was confirmed. Cumulative
in-field control, LRC, freedom from distant metastasis
(FFDM), freedom from progression (FFP) and overall
survival (OS) were calculated using Kaplan-Meier curves,
and two or more Kaplan-Meier curves were compared
using log-rank tests. Differences between three or more
groups were evaluated by the Kruskal-Wallis test. Univari-
ate and multivariate Cox regression analyses were used to
determine whether variables had prognostic value or not.
Correlation coefficients for all variables were calculated toFigure 2 Ninety lung tumors were divided into four groups according
42 tumors was 14.7 mm (range, 4.3-36.0 mm), and the tumors were divided a
groups.avoid multicollinearity. A p-value < 0.05 was defined as
significant in all tests. JMP v.11.0.0 (SAS Institute, Cary,
NA) was used for statistical analyses.
Results
Measurement results
Among the 90 tumors, 42 tumors were attached to the
pleura, 21 had pleural indentation and 27 had neither
pleural attachment nor pleural indentation (no attach-
ment group). The median length of attachment of the 42
tumors was 14.7 mm (range, 4.3-36.0 mm), and the tu-
mors were separated into two groups at the median value:
a broad attachment group and a narrow attachment group
(Figure 2).
Treatment results
The median follow-up period for survivors was
46.1 months (range: 18.5-90.2 months) and that for
all patients was 39.0 months (range: 3.3-90.2 months).
During follow-up, there were in-field failure in 7 of
the 90 tumors (7.7%), involved lobar failure in 14 of
the 89 lobes (15.7%), regional lymph node failure in
12 of the 87 patients (13.7%), locoregional failure in
22 of the 87 patients (25.2%), distant metastasis in 23
of the 87 patients (26.4%) and any failure in 38 of the
87 patients (43.6%). The median time to in-field failure
was 26.1 months (range: 8.9-66.9 months), the median
time to locoregional failure was 26.7 months (range:
8.7-66.9 months) and the median time to any failure
was 28.8 months (range: 3.3-79.5 months). Of 7 in-field
failure cases, 5 cases occurred in the broad attachment
group, 1 case occurred in the narrow attachment group
and 1 case occurred in no attachment group. Three of
the 5 failure cases in the broad attachment group and
the failure case in the narrow attachment group recurred
with attachment to the pleura, and the other three in-field
recurrences were in intrapulmonary region. Forty-three
patients died during follow-up: 22 died of primary diseaseto attachment status. The median length of positive attachment of
t the sample median into broad attachment and narrow attachment
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trol, LRC, FFDM, FFD and OS rates were 91.2% (95%
confidence interval [CI]: 81.4-96.0%), 75.3% (95% CI:
63.5-84.2%), 76.3% (95% CI: 64.8-84.9%), 63.8% (95% CI:
51.9-74.3%) and 68.6% (95% CI: 57.8-77.7%), respectively.
The median periods of FFDM, FFD and OS were 79.5,
49.1 and 65.0 months, respectively. Pneumonitis of grade
2 occurred in 11 patients, and pneumonitis of grade 3
occurred in 2 patients.
The median BED10 values in the broad attachment, nar-
row attachment, pleural indentation and no attachment
groups were 98.5 Gy10 (range: 83.3-107.5 Gy10), 102.4 Gy10
(range: 82.6-106.9 Gy10), 103.3 Gy10 (range: 74.2-121.0 Gy10)
and 101.8 Gy10 (range: 91.5-106.0 Gy10), respectively (p =
0.06). The broad attachment group had significantly lower
in-field control, LRC and FFP rates than those in the narrow
attachment group, pleural indentation group and no attach-
ment group (p < 0.01, p < 0.01 and p < 0.01, respectively),
but there were no significant differences between the narrow
attachment group, pleural indentation group and no attach-
ment group in in-field control, LRC and FFP (p = 0.93, p =
0.45 and p = 0.90, respectively; Figure 3).
Univariate and multivariate analyses
The results of univariate and multivariate analyses for
in-field control, LRC, FFDM and FFD are shown in
Table 2. In univariate analyses, attachment status (broadFigure 3 The broad attachment group showed significantly lower curve
p < 0.01 and p < 0.01, respectively, log-rank test).attachment group vs. the others; p < 0.01, hazard ratio
[HR]: 11.5, 95% CI: 2.72-81.5), tumor diameter (per 1 cm
increase; p < 0.01, HR: 3.71, 95% CI: 1.47-9.72) and SBRT
dose (BED10: > 102 Gy10 vs. ≤ 102 Gy10; p = 0.02, HR: 0.13,
95% CI: 0.01-0.79) for in-field control, attachment status
(broad attachment group vs. the others; p < 0.01, HR: 4.60,
95% CI: 1.91-10.8) and tumor diameter (per 1 cm increase;
p < 0.01, HR: 2.25, 95% CI: 1.30-3.83) for LRC, attachment
status (broad attachment group vs. the others; p = 0.01,
HR: 3.02, 95% CI: 1.22-7.19) and tumor diameter (per
1 cm increase; p < 0.01, HR: 2.01, 95% CI: 1.19-3.33) for
FFDM, and attachment status (broad attachment group
vs. the others; p < 0.01, HR: 3.78, 95% CI: 1.87-7.40) and
tumor diameter (per 1 cm increase; p < 0.01, HR: 2.02,
95% CI: 1.32-4.81) for FFP were significant predictors. In
multivariate analyses, tumor diameter (per 1 cm increase;
p = 0.04, HR: 3.65, 95% CI: 1.00-14.1) and SBRT dose
(BED10: > 102 Gy10 vs. ≤ 102 Gy10; p = 0.02, HR: 0.10, 95%
CI: 0.01-0.75) were significant independent predictors of
in-field control, broad attachment was a negative, inde-
pendent predictor of LRC (p = 0.02, HR: 3.08, 95% CI:
1.15-8.27) and FFP (p = 0.01, HR: 2.66, 95% CI: 1.21-5.73),
and no significant factor for FFDM emerged (Table 2).
Discussion
This study was an important and, to the best of our
knowledge, the first analysis of the outcomes of SBRTs in in-field control (a), LRC (b) and FFP (c) than the others (p < 0.01,
Table 2 Univariate analysis (upper column) and multivariate analysis (lower column) using Cox regression




P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI
Attachment status: broad attachment
vs. others
<0.01* 11.5 2.42-81.5 <0.01* 4.60 1.91-10.8 0.01* 3.02 1.22-7.19 <0.01* 3.78 1.87-7.40
Gender: female vs. male 0.89 1.11 0.15-5.20 0.29 0.57 0.16-1.54 0.57 1.29 0.49-3.03 0.54 0.79 0.35-1.62
Diagnosis: pathological vs. clinical 0.17 3.59 0.60-68.1 0.15 2.00 0.78-6.13 0.19 1.81 0.75-5.09 0.11 1.79 0.87-4.04
Tumor diameter (cm): per 1 cm
increase
<0.01* 3.71 1.47-9.72 <0.01* 2.25 1.30-3.83 <0.01* 2.01 1.19-3.33 <0.01* 2.02 1.32-3.07
Perfomance status: 0-1 vs. 2-3 0.97 0.96 0.15-18.5 0.88 1.09 0.36-4.71 0.38 1.81 0.52-11.3 0.48 1.42 0.56-4.81
SBRT dose (BED10): > 102 Gy10
vs. ≤ 102 Gy10
0.02* 0.13 0.01-0.79 0.59 1.25 0.54-3.05 0.88 0.94 0.45-2.02 0.77 0.90 0.47-1.75
Prescription: isocenter vs. D95 0.53 1.88 0.30-36.3 0.94 0.96 0.35-3.01 0.79 0.88 0.35-2.48 0.27 0.64 0.30-1.45
Attachment status: broad attachment
vs. others
0.15 4.00 0.59-35.6 0.02* 3.08 1.15-8.27 0.19 1.93 0.70-5.29 0.01* 2.66 1.21-5.73
Tumor diameter (cm): per 1 cm
increase
0.04* 3.65 1.00-14.1 0.12 1.67 0.86-3.10 0.09 1.68 0.91-3.00 0.06 1.59 0.96-2.55
SBRT dose (BED10): > 102 Gy10 vs.
≤ 102 Gy10
0.02* 0.10 0.01-0.75 n.s. n.s. n.s
Abbreviations: D95, doses covering 95% of the planning target volume; BED, biological effective dose; HR, hazard ratio; CI, confidence interval; n.s, not significant.
*p < 0.05.
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though pleural invasion status has been widely known as
a significant predictor for OS after a lung operation,
there have been few attempts to analyze the prognostic
value of pleural invasion status or an alternative status
after SBRT, presumably because gross pathology or micro-
scopic pathology is not possible after SBRT [3-5,17]. There-
fore, an alternative method using CT images in which the
length of tumor attachment to the pleura was measured at
the lung window was used in this study.
Tumors with broad attachment to the pleura showed
significantly worse in-field control, LRC, FFDM and FFD
in univariate analysis and the log-rank test (Table 2,
Figure 3). In multivariate analysis for in-field control,
LRC, FFDM and FFD, a tumor with broad attachment
was a negative independent predictor of LRC and FFD.
These results indicated that length of tumor attachment
to the pleura measured with pretreatment CT images at
the lung window might be an important prognostic factor.
However, no significant independent factor for FFDM was
found, and since 21 of the 87 patients died of other causes,
the follow-up periods were thus shortened. More patients
and longer follow-up are needed for further analyses.
Although Kaplan-Meier in-field control curves were
significantly lower in the broad attachment group, only
SBRT dose and tumor diameter were independent prog-
nostic factors for in-field tumor control. This would be
because patients in the broad attachment group tended
to be prescribed lower SBRT doses at the isocenter.
The results for prognostic significance of SBRT dose
and tumor diameter confirmed previous findings [8,15].In-field tumor control was influenced by SBRT dose and
tumor diameter, and therefore dose escalation for larger
tumors was resonable. In addition, although no significant
factor for involved lobar failure emerged, the broad attach-
ment group tended to show lower involved lobar control
in univariate analysis (p = 0.06, HR: 3.08, 95% CI: 0.92-
9.36). This result possibly indicates that tumors with broad
attachment should be considered larger target volumes.
It is important to distinguish stage IA from IB because
adjuvant chemotherapy is sometimes considered after
surgical resection for stage IB NSCLC [19]. Our results
showed that broad attachment was an independent un-
favorable predictor for LRC and FFP, and this suggested
that tumors with broad attachment might also be regarded
as stage IB and considered for additional chemotherapy
after or concurrent with SBRT. Although most of our
patients were elderly (median age, 78 years), additional
chemotherapy would be beneficial even for elderly pa-
tients because concurrent chemoradiotherapy for stage
III elderly patients (median age, 77 years) using daily
low-dose carboplatin showed a survival benefit com-
pared with radiotherapy alone [20]. Therefore, concur-
rent or adjuvant chemotherapy would be beneficial for
improvement of LRC and FFP.
It has been shown that attachment length-to-maximum
tumor diameter ratios on presurgical CT images favorably
reflected pathological difference: pl1, pl2 and pl3 [6].
However, our study showed that attachment length to
the pleura was more discriminative for LRC than attach-
ment length-to-maximum tumor diameter ratio (p = 0.0001
and p = 0.0090, respectively, log-rank test). This difference
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guish pl1 from pl0 in stage I NSCLC. Thus, although our
results were not based on pathological findings, measure-
ment of tumor attachment to the pleura would be helpful
for treatment of SBRT.
No significant differences for in-field tumor control,
LRC and FFP were seen between the no attachment
group, narrow attachment group and pleural indentation
group (Figure 2). In surgical studies, lung cancer with
pleural indentation was sometimes excluded from a lim-
ited pulmonary resection because of its invasiveness to the
pleura [21,22]. However, our study did not show the im-
portance of pleural indentation. Since SBRT was shown
to be as effective as sublobectomy or possibly lobectomy
using propensity-score matched analysis, pleural indenta-
tion status might not be an issue in SBRT [23,24]. The
spread of a low dose outside the target volume may be
effective. Our inclusion criteria for eliminating mainly
ground glass component tumors, short follow-up periods
or some non-high-resolution CT images might have hin-
dered the prognostic value of pleural indentation. A tumor
with narrow attachment to the pleura was not a significant
factor unlike a tumor with broad attachment. Narrow
attachment would reflect tumor invasion to the pleura
beneath the elastic layer, or would seem attaching to
the pleura by partial volume effect of CT images.
This study had some limitations. First, this study was a
retrospective, single institute analysis with a limited sam-
ple size. Second, high-resolution CT images were avail-
able for only 37 of the 90 tumors and therefore the
cut-off point in this study was limitative. Ideally, to find a
reliable cut-off point, only high-resolution CT images with
a sufficient sample size should be used and a receiver
operating characteristic curve should be plotted. Finally,
various treatment protocols were included in the analysis.Conclusions
In conclusion, pleural attachment status on a pretreat-
ment CT image was an important predictor, and broad
attachment to the pleura was a negative independent
predictor of LRC and FFP. Pleural attachment status
might be a good target of additional therapy, but further
evidence is needed.Abbreviations
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